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Background/aim: Osteosarcoma requires an angiogenesis process. CYR61 is one of the extracellular signaling molecules that promote
angiogenesis, tumor growth, and the malignancy of osteosarcoma. In the present study, we investigate the CYR61 gene variations in
osteosarcoma and their correlations with clinicopathological findings.
Materials and methods: We performed variation analysis of the CYR61 gene in 58 patients with osteosarcoma. With an aim to ascertain
the variety of variations in exons 2, 3, 4, and 5 of the CYR61 gene in osteosarcoma, we did a PCR-SSCP followed by DNA sequencing.
Results: In osteosarcoma the CYR61 gene variations found were 18.96% (11/58) in exon 2, 3.44% (2/58) in exon 3, 8.62% (5/58) in
exon 4, and 15.51% (9/58) in exon 5. In our variation analysis, we detected one missense variation in exon 2 (Arg47Trp), one silent
variation in exon 3 (Lys152Lys), one missense variation in exon 4 (Phe213Leu), and two missense variations in exon 5 (Gly315Arg and
Asp339Asn). The overall CYR61 variation frequency in exons 2, 3, 4, and 5 was determined to be 46.55% (27/58).
Conclusion: Our study specifies the role of CYR61 gene variation in osteosarcoma. The result signifies that CYR61 might be used as a
prognostic/diagnostic marker in osteosarcoma patients.
Key words: Osteosarcoma, CYR61, PCR, SSCP, sequencing, gene variation

1. Introduction
Osteosarcoma, the most common primary malignant
bone tumor, commonly arises in the metaphysis of long
bones (1). Normally, osteosarcoma has a moderate rate of
incidence, with 10 to 26 cases per million worldwide every
year (2).
The 5-year survival in osteosarcoma in the first half of
the 20th century was less than 20% (3). Amputation of the
involved extremity aimed at compartmental resection was
initially the mainstay of treatment (4). The primary target was
to decrease the tumor load, although this does not prevent
metastasis and pulmonary metastasis via hematogenous
spread, which was the major cause of mortality in these
patients. In a normal course, osteoblastic cells are responsible
for the production of the bony matrix. The same occurs with
these osteogenic cells in cancerous bones, the difference
being in the maturation and strength of bone matrix thus
produced, i.e. the bone matrix of a bone with osteosarcoma
is not as strong as that of normal bones (5). Tumors,
regardless of whether they are benign or malignant, can lead
to pathological fractures of the involved bone by virtue of
* Correspondence: as29762@gmail.com

their potential to replace normal bony tissues, rendering
them weak and prone to fracture. Osteosarcoma has five
different histological types and their severity and prognosis
varies accordingly. When diagnosed, it is usually in the late
stages with high grades of severity, which makes salvage of
the involved limbs difficult. Osteosarcomas originate from
mesenchymal cells having osteoblastic features. Although
the incidence of this bone tumor is low in the general
population, unfortunately it is the most often diagnosed and
lethal bone cancer in young adults (6). Osteosarcoma is a
highly malignant osteoid-forming spindle cell sarcoma of
the bone. Sometimes genetic variations may be linked with
an increased risk of osteosarcoma (7).
The first discovered CCN protein, i.e. CYR61, also
known as CNN1, was initially believed to be a classic
growth factor. Later studies established that CCN1, instead
of being a potent growth factor, also acted as a stimulator
for some other growth factors, such as fibroblast growth
factor and platelet-derived growth factor (8).
Though osteosarcoma can occur in any bone, the
metaphysis of long bones is a common site of its occurrence
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(80%–90%), with a particular predilection for distal
femoral metaphyses (35%), proximal tibial metaphyses
(20%), and proximal humeral metaphyses (10%). In
children, osteosarcoma accounts for 5% of all malignant
bone tumors, with peak occurrence between the ages of
10 to 24 years (9). When symptomatic, it usually presents
with localized pain, swelling, deformity, or a pathological
fracture. The most common malignant bone tumors in
children are osteosarcomas, which collectively make up
90% of pediatric bone tumors (10). The CYR61 proteins are
composed of extracellular matrix-associated proteins that
play crucial roles in skeletal development, wound healing,
fibrosis, and cancer (11). The CYR61 proteins have four
conserved cysteine-rich modular domains that trigger
the processes of cell adhesion, proliferation, migration,
differentiation, and survival via direct binding to specific
integrin receptors and heparin sulfate proteoglycans (9). The
effects of these processes are commonly regulated through
signaling via integrins, vascular endothelial growth factor,
bone morphogenetic protein, Wnt, and Notch pathways. In
addition, current studies suggest that CYR61 proteins may
affect progression of secondary metastatic bone tumors by
moderating the bone microenvironment (11,12).
CYR61 is a product of an immediate and early gene that
induces cell migration, mediates cell adhesion, enhances
growth factor-induced DNA synthesis in fibroblasts and
endothelial cells, stimulates chemotaxis of fibroblasts
and endothelial cells, and increases the chondrogenesis
in mesenchymal cells (13–15). The expression of
CYR61 protein enhances neovascularization and tumor
formation of human tumor cells in immunodeficient mice
significantly (16–18).
Overall, a better understanding of CYR61 gene
protein-regulated pathways in osteoblast/osteoclast can
improve our knowledge of the pathogenesis of the disease
and can potentially aid in developing CYR61 proteinbased diagnostic marker and therapeutic strategies for
the management of osteosarcoma. Therefore, study of the
CYR61 protein in patients with osteosarcoma is being

considered as a promising biomarker for future research
work.
2. Materials and methods
2.1. Specimen collection
Fifty-eight osteosarcoma specimens were collected from
the Department of Orthopedic Surgery, King George’s
Medical University, Lucknow, Uttar Pradesh, India. In
such cases, fine-needle aspiration biopsy yielded positive
cytology and based on these results, the tissue was
diagnosed as osteosarcoma. The 58 cases were diagnosed
as osteosarcoma using quantitative, qualitative, and
histological grade according to Enneking et al. (19) and
Bickels et al. (20). This study was carried out from May
2011 to March 2015. The study was approved by the
institutional ethics committee. Before enrollment in the
study, each subject’s written informed consent was obtained
in response to a fully written and verbal explanation of the
nature of the study.
2.2. DNA isolation
Samples were collected from 58 biopsy tissues diagnosed as
osteosarcoma based on categorized and grading as per the
internationally accepted standard. The genomic DNA was
extracted by a Fermentas DNA extraction kit (Germany)
and stored at –80 °C.
2.3. Genomic DNA PCR amplification
Primers for the CYR61 gene were designed using GENE
TOOL software. PCR was performed in a gradient
thermocycler (ABI, USA) using thin-walled 0.2-mL PCR
tubes. The final volume of the PCR reaction mixture was
25 µL, containing 10–40 ng of genomic DNA, 1 pmol of
forward and reverse primers, and 2X master mix (ABI,
USA) at a concentration of 1X. Amplification was carried
out using different primers for different exons (Table 1)
and different PCR programs (Table 2) for different exonic
regions of the CYR61 gene. A further 5 µL of the amplified
product was checked on 2% agarose gel with ethidium
bromide staining.

Table 1. PCR primers of the CYR61 gene.
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Exon

Forward/reverse primers

Amplicon size (bp)

2

F 5’-GCGCTCTCCACCTGCCCC-3’
R 5’-GCTCTGAAGGGGATCTGCAGA-3’

213

3

F 5’-CAGTCAGAGGGCAGACCCTGT-3’
R 5’-AGCTCACTGAAGCGGCTCCCT-3’

354

4

F 5’-TTAGGAATGGAGCCTCGC-3’
R 5’-GTGTACAGCAGCCTGAAA-3’

207

5

F 5’-AAGGGCAAGAAATGCAGCAAG-3’
R 5’-ACATTCACAAATTTAGGGAC-3’

300
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Table 2. PCR programs of different exons of the CYR61 gene.
Exon

Step 1 (denaturation)

Step 2 (annealing)

Cycles

Step 3 (extension)

2

95 °C→ 7 min

95 °C→ 1 min

55 °C→ 50 s

72 °C→ 1 min

35

72 °C→ 5 min

3

94 °C→ 8 min

94 °C→ 1 min

56 °C→ 30 s

72 °C→ 1 min

40

72 °C→ 7 min

4

95 °C→ 5 min

95 °C→ 1 min

56 °C→ 1 min

72 °C→ 1 min

35

72 °C→ 8 min

5

95 °C→ 10 min

95 °C→ 1 min

58 °C→ 45 s

72 °C→ 1 min

41

72 °C→ 5 min

2.4. Variation screening of CYR61 exons by SSCP
Single-strand conformational polymorphism (SSCP)
analysis was performed according to Orita et al. (21,22)
with minor modifications. Samples were denatured at 95 °C
for 5 min with denaturing dye and immediately transferred
to ice. Next, 25 µL of amplified PCR product was loaded
along with 25 µL of denaturing dye on 8% polyacrylamide
gel. The gel was run in precooled 1X TBE buffer. The gel
tank was placed in a cold room at 4 °C and run for 8–10 h
at 130 V. DNA on the gel was stained after electrophoresis
with silver stain. Electrophoresis mobility shifts in singlestranded or double-stranded DNA products from patients
were detected by comparison with DNA products from
normal controls run in adjacent lanes (Figure 1).
2.5. CYR61 variation analysis by sequencing
Amplified fragments of all samples were characterized by
automated sequencing. The PCR product of each sample
was first purified and then submitted in a quantity of 25
µL with 10 pmol of appropriate primer. The sequencing
was performed by automated direct DNA sequencing
technique, which incorporates fluorescently labeled dideoxy-nucleotides during cycle sequencing and separates
the resulting products by capillary electrophoresis for
detection on an ABI 3730XL DNA Analyzer (Applied
Biosystems, USA). Multiple alignment and sequence
analysis were done using BLAST, BioEdit, FinchTV, and
Auto Assembler Software (Applied Biosystems, USA).
Variations were reconfirmed by sequencing amplicons in
both directions and in independent second samples.

3. Results
A total of 58 cases were diagnosed as osteosarcoma
according to Enneking et al. (19) and Bickels et al.
(20). The mean age of these patients was 20 ± 3.90
years, ranging from 10 years to 30 years. Four missense
variations were detected in 25 osteosarcoma cases in
exons 2, 4, and 5 and one silent variation was detected
in two osteosarcoma cases in exon 3 (Figures 2–5). One
missense variation was detected in exon 2 (Arg47Trp),
one silent variation in exon 3 (Lys152Lys), one missense
variation in exon 4 (Phe213Leu), and two missense
variations in exon 5 (Gly315Arg and Asp339Asn). We
observed the CYR61 gene missense variation rates in
grade G1 (33.33% in a total of 10/30 cases), grade G2
(43.75% in a total of 7/16 cases), and grade G1/G2
(66.67% in a total of 8/12 cases). CYR61 gene silent
variations were found in grade G1 (6.67% in a total of
2/30 cases). Details of the clinical data and missense
and silent variations in exons 2, 3, 4, and 5 are shown
in Table 3. Out of 58 osteosarcoma cases, 39 were
found to have variations by a shift in DNA position on
SSCP-PAGE with respect to DNA from healthy donors
(Figure 1). These results, after comparison to previously
reported findings, are shown in Table 4. The CYR61 gene
missense variation in exon 3 for codon Lys152Lys, exon 4
for codon Phe213Leu, and exon 5 for codons Gly315Arg
and Asp339Asn are described here for the first time.

Figure 1. SSCP-PAGE showing electrophoresis mobility shift bands on native PAGE.
Control: L1; no shift bands in L2–L5, L7, and L8; and shift bands in L6 (arrow).
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Figure 2. Amino acid sequences of exons 2, 3, 4, and 5 of the CYR61 gene. The wild-type sequence is shown above the cases.
Missense and silent variations are shown in colored squares.

Figure 3. Nucleotide sequence chromatograms of CYR61 gene missense and silent variations: A) exon
2 nucleotides C→T, resulting in the amino acid substitution Arg47Trp; B) exon 3 nucleotides A→G,
resulting in the amino acid substitution Lys152Lys; C) exon 4 nucleotides T→A, resulting in the amino
acid substitution Phe213Leu; D) exon 5 nucleotides G→C, G→A, resulting in the amino acid substitutions
Gly315Arg and Asp339Asn.
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Figure 4. Variation analysis of the CYR61 gene showing changes of nucleotides and amino acids: A) exon 2 missense variation
codon Arg47Trp (CGG→TGG); B) exon 3 silent variation codon Lys152Lys (AAA→AAG); C) exon 4 missense variation codon
Phe213Leu (TTT→TTA); D) exon 5 missense variation codon Gly315Arg (GGT→CGT) and codon Asp339Asn (GAT→AAT).

Figure 5. Location of CYR61 gene variations describes our results: missense and silent variations in exons 2, 3, 4, and 5 and the
distinctive molecular domains encompass functional structures, e.g., NH2-terminal, signaling peptide (SP), insulin-like growth
factor binding protein domain (IGFBP), von Willebrand factor domain (VWC), thrombospondin-homology domain (TSP-1),
cysteine knot domain (CT), and COOH terminal, correspondingly.

3.1. Analysis of variations in exons 2, 3, 4, and 5
In 58 osteosarcoma cases, 25 samples showed a shift
in position in native SSCP-PAGE in exon 2. These were
directly sequenced by an automated sequencer. Eleven
missense variations were detected in 11 osteosarcoma
patients (Figures 2–4; Table 3).
Out of 58 osteosarcoma cases, 10 samples displayed
a shift in position in native SSCP-PAGE in exon 3. These

were directly sequenced by an automated sequencer.
Two silent variations were detected in two osteosarcoma
patients (Figures 2–4; Table 3).
In 58 osteosarcoma cases, 13 samples showed a shift
in position in native SSCP-PAGE in exon 4. These were
directly sequenced by an automated sequencer. Five
missense variations were detected in five osteosarcoma
patients (Figures 2–4; Table 3).
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Table 3. Details of the clinical data and CYR61 gene variations in osteosarcoma cases.
No. of
cases

Grade

Stage

Codon
exon 2

10

G1

IA, IB

07

G2

08
02

Codon
exon 3

Codon
exon 4

Codon
exon 5

Arg47Trp

Phe213Leu

Gly315Arg

IIA, IIB

Arg47Trp

Phe213Leu

Gly315Arg
Asp339Asn

G1/G2

III

Arg47Trp

Phe213Leu

Gly315Arg
Asp339Asn

G1

IA, IB

Lys152Lys

IA & IIA: Intracompartmental.
IB & IIB: Extracompartmental.
III: Either grade with metastases.
Table 4. Variations detected in our study of exons 2, 3, 4, and 5 in the CYR61 gene and their allele frequency.
Exons

Variations in aa

Variations in codons

Variation’s ID or references

Allele frequency

Exon 2

Arg47Trp

CGG → TGG

[23]

0.517

Exon 3

Lys152Lys

AAA → AAG

Not reported

0.275

Exon 4

Phe213Leu

TTT → TTA

rs755958207

0.543

Exon 5

Gly315Arg

GGT → CGT

rs532164537

0.560

Exon 5

Asp339Asn

GAT → AAT

rs375944529

0.448

Out of 58 osteosarcoma cases, 23 samples showed a
shift in position in native SSCP-PAGE in exon 5. These
were directly sequenced by an automated sequencer. Nine
missense variations were detected in nine osteosarcoma
patients (Figures 2–4; Table 3).
For these findings, where we found variations around
the protein, it was important to address where in the
protein these variations were located in order to determine
the possible implications of these variations in protein
function. Therefore, we analyzed the protein sequence
using BioEdit and Pyre2 software. The Arg47Trp variation
for exon 2 is located on the insulin-like growth factor
binding protein domain (IGFBP), the Lys152Lys silent
variation for exon 3 is located on the von Willebrand
factor domain (VWC), the Phe213Leu variation for exon
4 is located on the thrombospondin-homology domain
(TSP-1), and the Gly315Arg and Asp339Asn variations for
exon 5 are located on the cysteine knot domain (CT) in
osteosarcoma cases.
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4. Discussion
To our knowledge, this study is the first in northern India
to report variations of the CYR61 gene in osteosarcoma
patients. Osteosarcoma is the most common primary
bone tumor. As it is a very fast-growing tumor with
metastasis in early stages, it becomes difficult to diagnose
it in initial stages. In almost all cases, micrometastasis in
the pulmonary system has already taken place by the time
a clinical diagnosis is made. This tumor is resistant to a
number of chemotherapeutic agents, which is responsible
for the treatment failure and high mortality rate of patients.
Previous molecular studies revealed several variations
in different types of patients from different ethnic groups.
Variations in exons 2, 3, and 4 of the CYR61 gene are less
frequently detected than in exon 5 in different types of
patients (23–25). However, during our variation analysis,
besides the detection of one missense variation in exon
2 (Arg47Trp), there was one silent variation in exon 3
(Lys152Lys), one missense variation in exon 4 (Phe213Leu),
and two missense variations in exon 5 (Gly315Arg and
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Asp339Asn). The overall CYR61 variation frequency in
exons 2, 3, 4, and 5 was determined to be 46.55% (27/58).
With these observations, our study supports the role of
CYR61 gene variation in osteosarcoma, and we concluded
that by virtue of its behavior in osteosarcoma patients, this
gene is justified for use as a prognostic/diagnostic marker.
We also recommend the CYR61 gene as a new drug
target for the treatment of osteosarcoma, though further
multicenter studies are needed to validate this.
As the CYR61 gene is located in 1p22.3 on chromosome
1, which has numerous translocations, it is reported to be
the most common region of chromosome involvement in
human cancers (26), especially in osteosarcoma cells, which
have a high percentage of polysomy in chromosome 1 (27).
Wittig et al. (28) suggested CYR61 as a candidate
gene responsible for drug resistance in melanoma.
Overexpression of CYR61 was observed to increase the
potential of resistance to chemotherapeutic drugs in
ovarian and breast cancer cells (29,30). Later on Fromigue
et al. (31) observed the antitumoral effect of the treatments
targeting the CYR61 gene, which also enhances the
potential of chemotherapy in bone tumors.
Fromigue et al. (31) also noticed the expression
level of CYR61, which is significantly higher in primary
osteosarcoma than in normal bone tissue. The CYR61
expression positively correlates with tumor invasiveness in
human osteosarcoma and attenuation of CYR61 reduces
cancer cell progression. Fromigue et al. also showed
that the overexpression of the CYR61 gene increases the
tumor behavior in osteosarcoma by acting on pulmonary
metastatic foci, both in number and size.

High expression levels of CYR61 were reported in
malignant melanomas, rhabdomyosarcomas, colon
adenocarcinomas, and bladder papillomas (21,32).
According to Xie et al., CYR61 also exhibited high levels
in malignant gliomas, which enhanced the tumorigenicity
(33). Overexpression of CYR61 was recently identified in
peritoneal metastases from human pancreatic cancer (34).
We also found a positive association of the CYR61 gene
with osteosarcoma, which raises speculation that CYR61
might play distinct roles in osteosarcoma with different
stages.
In conclusion, using a translational approach, we
identified the missense variations (F213L and G315R) in
osteosarcoma patients with linkage to CYR61, an important
factor in carcinogenesis and its subsequent progression.
The present study supports an important role of the CYR61
gene in human osteosarcoma and we recommend further
multicenter studies with large sample sizes to confirm
the roles of these variations in osteosarcoma patients and
to establish an association. This gene can also provide a
molecular target that will open the fields for a novel and
effective therapeutic strategy to reduce the mortality and
morbidity associated with the disease. The results signify
that the CYR61 gene might be used as a prognostic/
diagnostic marker in osteosarcoma patients.
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